Can patients with breast nodules take semaglutide?
Generally, most patients with breast nodules can take semaglutide, but specific medication use should be determined according to a doctor's advice.
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that lowers blood glucose by stimulating insulin secretion and reducing glucagon secretion. It is primarily used for treating diabetes, particularly for glycemic control in adult patients with type 2 diabetes. Additionally, it helps reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes who also have cardiovascular disease.
Breast nodules are mostly benign lesions and typically do not involve endocrine or metabolic abnormalities. Therefore, in theory, using semaglutide in patients with breast nodules is unlikely to cause direct adverse effects due to the drug’s impact on the endocrine system. If a patient with breast nodules also has type 2 diabetes or obesity, semaglutide may be used under medical supervision.
However, semaglutide should not be used if the breast nodule is accompanied by symptoms such as pain, redness, or swelling, or if the patient has contraindications such as allergy to semaglutide or acute pancreatitis.
Patients with breast nodules should also maintain positive emotional well-being, engage in appropriate physical activity, avoid external forces such as pressure or trauma to the breast, and pay attention to balanced diets and adequate nutritional intake.